TGTX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
240.3M
+17.3%
204.9M
+6.4%
192.6M
+19.1%
161.7M
+14.6%
141.1M
Cost of Revenue
41.2M
+22.9%
33.5M
-12.1%
38.1M
+35.8%
28.1M
+48.3%
18.9M
Gross Profit
199.1M
+16.2%
171.4M
+11.0%
154.4M
+15.6%
133.6M
+9.3%
122.2M
Operating Expenses
177.5M
+29.9%
136.6M
+31.4%
103.9M
-0.3%
104.3M
+19.3%
87.4M
R&D
87.3M
+100.5%
43.5M
+77.1%
24.6M
-39.9%
40.9M
+48.8%
27.5M
SG&A
90.2M
+352.1%
19.9M
-30.3%
28.6M
+131.9%
12.4M
-79.4%
59.9M
Operating Income
21.7M
-37.7%
34.8M
-31.1%
50.5M
+72.0%
29.4M
-15.7%
34.8M
EBITDA
21.7M
-37.6%
34.8M
-30.9%
50.4M
+70.6%
29.5M
-15.3%
34.9M
Net Income
7.8M
-60.7%
19.8M
-14.2%
23.0M
-94.1%
390.9M
+1286.8%
28.2M
EPS (Basic)
$0.05
-64.3%
$0.14
-17.6%
$0.17
-93.7%
$2.69
+1315.8%
$0.19
EPS (Diluted)
$0.05
-58.3%
$0.12
-14.3%
$0.14
-94.2%
$2.43
+1329.4%
$0.17
Shares (Diluted)
157.3M
-1.7%
160.1M
+0.5%
159.3M
-1.0%
161.0M
-1.0%
162.6M
TG Therapeutics (TGTX) โ€” Financials